Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: Results from the University of Washington Rapid Autopsy Series

Journal of Bone and Mineral Research

Volumn 28, Issue 2, 2013, Pages 333-340

  Morrissey, Colm ^a   Roudier, Martine P ^b   Dowell, Alex ^a   True, Lawrence D ^b   Ketchanji, Melanie ^a   Welty, Christopher ^a   Corey, Eva ^a   Lange, Paul H ^a,c   Higano, Celestia S ^a,b   Vessella, Robert L ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

androgen deprivation; bisphosphonates; Histomorphometry; osteoclasts; prostate cancer metastasis

Indexed keywords

ALENDRONIC ACID; METHACRYLIC ACID METHYL ESTER; PAMIDRONIC ACID; PARAFFIN; ZOLEDRONIC ACID;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DEMINERALIZATION; BONE MASS; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MALE; MORPHOMETRICS; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; TREATMENT DURATION; TUMOR LOCALIZATION; TUMOR VOLUME;

AGED; ANDROGEN ANTAGONISTS; AUTOPSY; BONE AND BONES; DIPHOSPHONATES; HUMANS; MALE; NEOPLASM METASTASIS; ORCHIECTOMY; OSTEOBLASTS; OSTEOLYSIS; PROSTATIC NEOPLASMS;

EID: 84872454871     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1749     Document Type: Article

References (20)

1. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ., Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000; 31: 578-83.
2. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM., Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol. 2008; 180: 1154-60.
3. Lange PH, Vessella RL., Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev. 1998; 17: 331-6.
4. Olson KB, Pienta KJ., Pain management in patients with advanced prostate cancer. Oncology (Williston Park). 1999; 3: 1537-49.
5. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS., Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005; 352: 154-64.
6. Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L., Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol. 2010; 184: 918-23.
7. Coleman RE., Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12: 6243s-9s.
8. Higano CS., Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?. Nat Clin Pract Urol. 2008; 5: 24-434.
9. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL., Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol. 2003; 34: 646-53.
10. Lebeau A, Muthmann H, Sendelhofert A, Diebold J, Lohrs U., Histochemistry and immunohistochemistry on bone marrow biopsies. A rapid procedure for methyl methacrylate embedding. Pathol Res Pract. 1995; 191: 121-9.
11. Recker RR., Bone histomorphometry: techniques and interpretation. Boca Raton, FL: CRC Press; p. 23-9. 1983.
12. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR., Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595-610.
13. Bartl R, Frisch B., Biopsy of bone in internal medicine: an atlas and sourcebook (current histopathology) Vol. 21. Boston, MA: Kluwer Academic Publishers; 1993.
14. Serpa NA, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL, Dos Reis RB, Pompeo AC, Giglio AD., Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2012; 15: 36-44.
15. Weinstein RS, Roberson PK, Manolagas SC., Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009; 360: 53-62.
16. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC., Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000; 88: 2961-78.
17. Hatoum HT, Lin SJ, Guo A, Lipton A, Smith MR., Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin. 2011; 27: 55-62.
18. Glantschnig H, Hampton RA, Lu P, Zhao JZ, Vitelli S, Huang L, Haytko P, Cusick T, Ireland C, Jarantow SW, Ernst R, Wei N, Nantermet P, Scott KR, Fisher JE, Talamo F, Orsatti L, Reszka AA, Sandhu P, Kimmel D, Flores O, Strohl W, An Z, Wang F., Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem. 2010; 285: 40135-47.
19. Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC., RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther. 2008; 7: 2160-9.
20. Tian X, Jee WS, Li X, Paszty C., Ke HZ. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone. 2011; 48: 197-201.